AET Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: AET Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $6.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AET Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $6.9M Trade | TransData Nexus

AET Laboratories Private Limited

Indian Pharmaceutical Exporter · Advanced Antifungals Specialist · $6.9M Total Trade · DGFT Verified

AET Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $6.9M across 3 products in 3 therapeutic categories. Based on 142 verified export shipments from Indian Customs (DGFT) records, AET Laboratories Private Limited is the #1 Indian exporter in 1 product including Posaconazole. Top exports include Posaconazole ($6.0M), Febuxostat ($536.1K), Vildagliptin ($331.5K).

AET Laboratories Private Limited — Export Portfolio & Destination Treemap

AET Laboratories Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is AET Laboratories Private Limited? — Company Overview & Market Position

AET Laboratories Private Limited, incorporated on September 24, 2003, is a private limited company based in Telangana, India. The company is registered under the Corporate Identification Number (CIN) U24239TG2003PTC041756. Its authorized share capital is ₹150,000,000, with a paid-up capital of ₹81,778,820. The registered office is located at Survey No.42, Gaddapotharam, Kazipally Industrial Area, Sangareddy, Telangana, 502319, India.

AET Laboratories specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has a workforce of approximately 304 employees as of April 5, 2024.

What Does AET Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Posaconazole$6.0M 2Febuxostat$536.1K

Product Portfolio — Top 3 by Export Value

AET Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Posaconazole	Advanced Antifungals	$6.0M	121	5.3%	1
2	Febuxostat	Lipid & Metabolism	$536.1K	13	1.1%	10
3	Vildagliptin	Advanced Diabetes Medications	$331.5K	8	3.3%	9

AET Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $6.9M. The company is the #1 Indian exporter in 1 product: Posaconazole. The top category is Advanced Antifungals (87.5% of portfolio), followed by Lipid & Metabolism (7.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

AET Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

The company's manufacturing facility is situated in the Kazipally Industrial Area of Sangareddy, Telangana. While specific production capacities and specializations are not publicly disclosed, the facility is equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections.

3Key Leadership

As of September 30, 2022, Swapnil Singh serves as the Managing Director of AET Laboratories Private Limited. Other key directors include Oliver Robert Alexander Schrader and Kristian Philip Ruepp, both appointed on March 6, 2019, and Dieter Schoenfeld, appointed on January 21, 2004. Dr. Georg Stark joined the board on September 1, 2015.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does AET Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

AET Laboratories Private Limited has established a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, facilitating market access and distribution. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed.

2Emerging Markets

AET Laboratories has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), enabling access to these regions and enhancing its global footprint.

3Geographic Strategy

The company's geographic strategy demonstrates a balanced approach, with a significant focus on advanced antifungal medications, particularly posaconazole, which constitutes 87.5% of its export value. This concentration indicates a strategic emphasis on specialized therapeutic areas, potentially reducing exposure to market fluctuations in other segments.

AET Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

AET Laboratories Private Limited has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), allowing for the export of its pharmaceutical products to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, seeking approval for marketing in the U.S. Specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed.

2WHO & EU GMP

The company's products have been prequalified by the World Health Organization (WHO), ensuring compliance with international quality standards. Additionally, AET Laboratories holds European Union Good Manufacturing Practice (EU GMP) certificates, affirming adherence to EU regulations for pharmaceutical manufacturing. The company's status with the European Directorate for the Quality of Medicines & HealthCare (EDQM) is not publicly disclosed.

3CDSCO & Indian Regulatory

AET Laboratories Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

AET Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the advanced antifungal medication segment, AET Laboratories Private Limited faces competition from other pharmaceutical companies specializing in similar therapeutic areas. The company's market share in posaconazole is 5.3%, indicating a competitive position within this niche market. Specific market share comparisons and head-to-head analyses with competitors are not publicly disclosed.

2Key Differentiators

AET Laboratories' key differentiators include its specialized focus on advanced antifungal medications, particularly posaconazole, and its established presence in both regulated and emerging markets. The company's WHO prequalification and EU GMP certifications further enhance its credibility and appeal to international clients.

3Strategic Position

AET Laboratories Private Limited's current strategic direction centers on the production and export of specialized pharmaceutical formulations, with a strong emphasis on advanced antifungal medications. The company's future outlook includes expanding its product portfolio and exploring new therapeutic areas to diversify its offerings and mitigate market risks.

Buyer Due Diligence Brief — Evaluating AET Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

AET Laboratories has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $6.9 million USD and 142 shipments across three therapeutic categories. The company's portfolio concentration, with the top five products accounting for 100% of its export value, indicates a focused approach to product offerings. Reliability indicators, such as on-time delivery and product quality, are not publicly disclosed.

2Certifications to Verify

Importers should verify the following certifications when considering AET Laboratories Private Limited as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure the company holds a valid World Health Organization Good Manufacturing Practice certification.

EU GMP Certification: Verify the company's compliance with European Union Good Manufacturing Practice standards.

Frequently Asked Questions — AET Laboratories Private Limited

How many pharmaceutical products does AET Laboratories Private Limited export from India?

AET Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Posaconazole ($6.0M), Febuxostat ($536.1K), Vildagliptin ($331.5K). Total export value is $6.9M.

What is AET Laboratories Private Limited's total pharmaceutical export value?

AET Laboratories Private Limited's total pharmaceutical export value is $6.9M, based on 142 verified shipments recorded in Indian Customs (DGFT) data.

In which products is AET Laboratories Private Limited the #1 Indian exporter?

AET Laboratories Private Limited is the #1 Indian exporter in 1 products: Posaconazole (5.3% market share).

What therapeutic categories does AET Laboratories Private Limited cover?

AET Laboratories Private Limited exports across 3 therapeutic categories. The largest are Advanced Antifungals (87.5%, 1 products), Lipid & Metabolism (7.7%, 1 products), Advanced Diabetes Medications (4.8%, 1 products).

Get Full AET Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.